Clinical Research Publications, Regulatory Guides, Industry Reports and Job Aids
Barnett's reference manuals, industry compendiums and job aids are designed to provide updates on important new developments in the industry. Following is a complete listing of our products.
Good Clinical Practice: A Question & Answer Reference Guide 2024/2025
Hear a conversation between Editor-in-Chief, Donna W. Dorozinsky, R.N., M.S.N., C.C.R.C. and Keith Dorricott, as they discuss Risk-Based Quality Management and share insights from the Good Clinical Practice: A Question & Answer Reference Guide on this important topic.
Listen to an Interview with Rob DiCicco, VP Portfolio Management, Transcelerate Biopharma Inc. and Editor-in-Chief, Donna W. Dorozinsky, R.N., M.S.N., C.C.R.C., as she discusses what's new in this edition, including new chapters, integrated global content, and our expert editorial team.
In the past several years we have seen the release of many new regulations and guidances throughout the world. We are coming out of a pandemic which has changed how we conduct and manage clinical trials, and we are dealing with an unstable world where research subjects are living in war torn regions. The 2024/2025 edition of Barnett’s Good Clinical Practice: A Question & Answer Reference Guide has been reorganized with added topics to address this new era of clinical research. Written by more than 20 subject matter experts in core clinical research areas, this industry-leading GCP reference guide answers over 1,500 of the most common and difficult questions regarding the interpretation and implementation of U.S. and international GCP standards for drugs, biologics, and medical device clinical trials.
Some highlights of the completely updated and expanded guide include:
- An all-new section on risk-based quality management (RBQM) and Quality by Design, which are receiving ever more emphasis from global regulators
- Emphasis on Quality Tolerance Limits (QTLs), Key Risk Indicators (KRIs) and approaches to outsourcing RBQM
- Updates specific to ICH E6 and E8 including the ICH E6 (R3) Draft
- Public comments from regulators and references to other industry guidance/sources
- Impact of the new Clinical Trial Regulations in the EU and how Clinical Trial Information System (CTIS) are used for SUSAR reporting in Europe
- Content covering Decentralized Clinical Trials (DCTs) and what evidence regulators require for data quality
- Questions and answers regarding the balancing of equity and equality in trials (including study design, patient recruitment, compensation structures)
- Details around the use of real-time data monitoring and participant engagement technologies and their ethical implications
- A new section on conducting a clinical trial during a pandemic and/or war including trial management, risk assessments, monitoring activities, investigational product management, informed consent, and site change considerations
- And much more…!
